Setting new standards in information exchange for the pharmaceutical and biotech industry
New York Times Op-Ed Columnist Frank Bruni Joins a Clinical Trial as a Care Option
March 7, 2018
In a recent Sunday Review article in The New York Times, op-ed columnist Frank Bruni asked himself, “Am I Going Blind?” After waking up one morning with what felt like “a blob of petroleum jelly in my right eye,” several hours passed before Mr Bruni finally accepted that something was wrong.
A visit to his ophthalmologist quickly led to a neuro-ophthalmologist. Here, Mr Bruni learned that he had likely suffered “a stroke of the eye” affecting the optic nerve in a condition called nonarteritic anterior ischemic optic neuropathy (NAION).
As a rare affliction affecting around one in 10,000 people, Mr Bruni’s neuro-ophthalmologist informed him she had nothing to offer him. Except perhaps one thing: a clinical trial of an experimental treatment. With no other treatment available, Mr Bruni decided to join the clinical trial as a care option.
Making clinical trials a care option is arguably the greatest challenges that healthcare and clinical research ecosystems can collaborate on in bringing patients closer to clinical trials. We continue our focus on this topic at the Clinical Research as a Care Option event on April 11th at the Boston Marriott Cambridge in Massachusetts. In the one-day program, we look at how to integrate clinical research into the overall continuum of patient care and ask, how do we bring clinical research closer to patients and vice versa.
We also address how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research at the Patients as Partners US conference. The two-day program takes place on March 15-16, 2018 in Philadelphia.
To read Mr Bruni’s article, click here: “Am I Going Blind?”